Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany; German Center for Cardiovascular Research (DZHK), Berlin, Germany.
Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany; German Center for Cardiovascular Research (DZHK), Berlin, Germany.
Prog Cardiovasc Dis. 2020 Sep-Oct;63(5):623-629. doi: 10.1016/j.pcad.2020.07.001. Epub 2020 Jul 5.
The intra-aortic balloon pump (IABP) has been in routine use for various cardiovascular indications for 5 decades. However, its regular use has been increasingly questioned. The aim of IABP counterpulsation is to enhance coronary blood flow and to reduce afterload of the left ventricle. In-vivo studies, however, provided insight into how physiological responses might counteract the desired effects of the device. Large randomized trials did not show benefit of IABP in the main indications such as infarct-related cardiogenic shock, high-risk myocardial infarction without shock and elective high-risk percutaneous coronary intervention. As these results are reflected differently in international guidelines and the interpretation of the evidence is heterogeneous, the frequency of IABP use differs considerably by region. Current research efforts predominantly focus on other active mechanical circulatory support devices making evidence-based approaches for possible final IABP niches more difficult.
主动脉内球囊反搏泵(IABP)已常规用于各种心血管适应证达 50 年。然而,其常规应用越来越受到质疑。IABP 反搏的目的是增加冠状动脉血流并降低左心室的后负荷。然而,体内研究提供了关于生理反应如何对抗设备所需效果的见解。大型随机试验并未显示 IABP 在主要适应证(如与梗塞相关的心源性休克、无休克的高危心肌梗死和选择性高危经皮冠状动脉介入治疗)中的获益。由于这些结果在国际指南中的反映不同,且证据的解释存在异质性,因此 IABP 的使用频率在不同地区有很大差异。目前的研究工作主要集中在其他主动机械循环支持设备上,使得基于证据的方法更难以确定 IABP 的最终适应证。